ストックスクリーナーアプリを入手
98.47
2.99%
-3.03
アフターアワーズ：
98.47
前日終値:
$101.50
開ける：
$100.37
24時間の取引高:
1.14M
Relative Volume:
0.91
時価総額：
$11.61B
収益：
$2.77B
当期純損益:
$286.61M
株価収益率:
41.90
EPS:
2.35
ネットキャッシュフロー:
$524.11M
1週間 パフォーマンス:
-0.24%
1か月 パフォーマンス:
+5.28%
6か月 パフォーマンス:
-18.44%
1年 パフォーマンス:
-10.09%
1日の値動き範囲:
$98.31
$101.36
1週間の範囲:
$97.84
$104.12
52週間の値動き範囲:
$87.70
$129.50
Revvity Inc Stock (RVTY) Company Profile
RVTY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
98.47 | 11.63B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
425.34 | 158.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.75 | 142.87B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
531.42 | 43.87B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.08 | 33.87B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
160.13 | 28.10B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-01 | アップグレード | UBS | Neutral → Buy |
| 2025-01-10 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-15 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-07-08 | 開始されました | Leerink Partners | Outperform |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-04 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-05-23 | 再開されました | Goldman | Buy |
すべてを表示
Revvity Inc (RVTY) 最新ニュース
Reflecting On Research Tools & Consumables Stocks’ Q1 Earnings: Revvity (NYSE:RVTY) - Yahoo Finance
Revvity (RVTY) Shares Soar 1.98% on Clinical Trial Success - AInvest
Evercore ISI Adjusts Price Target on Revvity to $115 From $116, Maintains Outperform Rating - MarketScreener
(RVTY) Trading Advice - news.stocktradersdaily.com
Revvity to Hold Earnings Call on Monday, July 28, 2025 - Business Wire
Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101? - simplywall.st
5 Insightful Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
What 9 Analyst Ratings Have To Say About Revvity - Benzinga
Barclays Keeps Their Buy Rating on Revvity (RVTY) - The Globe and Mail
Is Revvity Stock Underperforming the Dow? - MSN
Is Revvity Stock Underperforming the Dow? A Case for Undervaluation and Growth - AInvest
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
How To Trade (RVTY) - news.stocktradersdaily.com
Are Revvity, Inc.'s (NYSE:RVTY) Mixed Financials Driving The Negative Sentiment? - simplywall.st
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows - SelectScience
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus By Investing.com - Investing.com Canada
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus - Investing.com
Transcript : Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Revvity To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET - Nasdaq
Wellington Management Group LLP Has $743,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com
Revvity gets FDA nod for its automated tuberculosis test - MSN
4 Mass. Rulings You May Have Missed In May - Law360
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows - Yahoo Finance
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Millennium Management LLC Trims Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Rise of the Undervalued: Why Revvity (RVTY) Is Poised for a Turnaround Play - AInvest
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers - Defense World
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen - Defense World
Zacks Research Forecasts Revvity’s Q1 Earnings (NYSE:RVTY) - Defense World
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Technology Networks
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Ameriprise Financial Inc. Increases Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Revvity's New Automated Platform Transforms Specialty Disease Testing with 20-Analyte Capability - Stock Titan
Element Biosciences Welcomes Dr. Madhuri Hegde to its Board of Directors - Business Wire
Revvity Inc (RVTY) 財務データ
収益
当期純利益
現金流量
EPS
13.81%
0.17%
大文字化:
|
ボリューム (24 時間):